Krishna Yeshwant - 16 Jun 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
16 Jun 2021, 19:40:48 UTC
Next SEC filing
22 Jun 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Andrew Ashe, Attorney-in-Fact

Key filing fact

Krishna Yeshwant filed Form 3 for Verve Therapeutics, Inc. (VERV) on 16 Jun 2021.

Key facts

  • This page summarizes Krishna Yeshwant's Form 3 filing for Verve Therapeutics, Inc. (VERV).
  • 0 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 16 Jun 2021, 19:40.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERV holding Derivative

Series A Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
16 Jun 2021
Ownership
By GV 2017, L.P
Underlying class
Common Stock
Underlying amount
6,320,905
Exercise price
Footnotes
F1, F2
VERV holding Derivative

Series A-2 Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
16 Jun 2021
Ownership
By GV 2019 L.P
Underlying class
Common Stock
Underlying amount
4,029,244
Exercise price
Footnotes
F3, F4
VERV holding Derivative

Series B Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
16 Jun 2021
Ownership
By GV 2019 L.P
Underlying class
Common Stock
Underlying amount
443,265
Exercise price
Footnotes
F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Series A Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

Footnote F2

The reported securities are held directly by GV 2017, L.P. GV 2017 GP, L.P. (the general partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the general partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2017 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2017 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2017, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2017, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose

Footnote F3

The Series A-2 Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

Footnote F4

The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Dr. Yeshwant is an affiliate of GV 2019 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2019, L.P. Dr. Yeshwant disclaims beneficial ownership of the shares held by GV 2019, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose

Footnote F5

The Series B Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

SEC remarks

Exhibit Index: 24.1 Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .